Top

Published in:

26-09-2022 | Stroke | Review

Role of alarmins in poststroke inflammation and neuronal repair

Authors: Seiichiro Sakai, Takashi Shichita

Published in: Seminars in Immunopathology | Issue 3/2023

Abstract

Severe loss of cerebral blood flow causes hypoxia and glucose deprivation in the brain tissue, resulting in necrotic cell death in the ischemic brain. Several endogenous molecules, called alarmins or damage-associated molecular patterns (DAMPs), are extracellularly released from the dead cells to activate pattern recognition receptors (PRRs) in immune cells that infiltrate into ischemic brain tissue following the disruption of the blood–brain barrier (BBB) after stroke onset. The activated immune cells produce various inflammatory cytokines and chemokines, triggering sterile cerebral inflammation in the ischemic brain that causes further neuronal cell death. Poststroke inflammation is resolved within several days after stroke onset, and neurological functions are restored to some extent as neural repair occurs around peri-infarct neurons. Clearance of DAMPs from the injured brain is necessary for the resolution of poststroke inflammation. Neurons and glial cells also express PRRs and receive DAMP signaling. Although the role of PRRs in neural cells in the ischemic brain has not yet been clarified, the signaling pathway is likely to be contribute to stroke pathology and neural repair after ischemic stroke. This review describes the molecular dynamics, signaling pathways, and functions of DAMPs in poststroke inflammation and its resolution.

Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19(1):24–32. https://doi.org/10.1016/j.smim.2006.12.004CrossRefPubMed

World Health Organization (2020) The top 10 cause of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Dreier JP, Reiffurth C (2015) The stroke-migraine depolarization continuum. Neuron 86(4):902–922. https://doi.org/10.1016/j.neuron.2015.04.004CrossRefPubMed

Lai TW, Zhang S, Wang YT (2014) Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol 115:157–188. https://doi.org/10.1016/j.pneurobio.2013.11.006CrossRefPubMed

Yang JL, Mukda S, Chen SD (2018) Diverse roles of mitochondria in ischemic stroke. Redox Biol 16:263–275. https://doi.org/10.1016/j.redox.2018.03.002CrossRefPubMedPubMedCentral

Neumann J et al (2015) Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. Acta Neuropathol 129(2):259–277. https://doi.org/10.1007/s00401-014-1355-2CrossRefPubMed

Oppenheim JJ, Yang D (2005) Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17(4):359–365. https://doi.org/10.1016/j.coi.2005.06.002CrossRefPubMed

Harris HE, Raucci A (2006) Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 7(8):774–778. https://doi.org/10.1038/sj.embor.7400759CrossRefPubMedPubMedCentral

Yang D, Han Z, Oppenheim JJ (2017) Alarmins and immunity. Immunol Rev 280(1):41–56. https://doi.org/10.1111/imr.12577CrossRefPubMedPubMedCentral

10.

Kim JB et al (2006) HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26(24):6413–6421. https://doi.org/10.1523/JNEUROSCI.3815-05.2006CrossRefPubMedPubMedCentral

11.

Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, Moskowitz MA (2008) Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28(5):927–938. https://doi.org/10.1038/sj.jcbfm.9600582CrossRefPubMed

12.

Zhang J et al (2011) Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42(5):1420–1428. https://doi.org/10.1161/STROKEAHACrossRefPubMed

13.

Yang QW et al (2011) HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 31(2):593–605. https://doi.org/10.1038/jcbfm.2010.129CrossRefPubMed

14.

Yanai et al (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462(7269):99–103. https://doi.org/10.1038/nature08512CrossRefPubMed

15.

Xiong XX, Gu LJ, Shen J, Kang XH, Zheng YY, Yue SB, Zhu SM (2014) Probenecid protects against transient focal cerebral ischemic injury by inhibiting HMGB1 release and attenuating AQP4 expression in mice. Neurochem Res 39(1):216–224. https://doi.org/10.1007/s11064-013-1212-zCrossRefPubMed

16.

Goldstein RS et al (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25(6):571–574. https://doi.org/10.1097/01.shk.0000209540.99176.72CrossRefPubMed

17.

Huang JM, Hu J, Ning C, Hu ML (2013) Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care 28(5):792–797. https://doi.org/10.1016/j.jcrc.2012.10.003CrossRefPubMed

18.

Schulze J, Zierath D, Tanzi P, Cain K, Shibata D, Dressel A, Becker K (2013) Severe stroke induces long-lasting alterations of high-mobility group box 1. Stroke 44(1):246–248. https://doi.org/10.1161/STROKEAHA.112.676072CrossRefPubMed

19.

Sapojnikova N, Kartvelishvili T, Asatiani N, Zinkevich V, Kalandadze I, Gugutsidze D, Shakarishvili R (1842) Tsiskaridze A (2014) Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim Biophys Acta 9:1379–1384. https://doi.org/10.1016/j.bbadis.2014.04.031CrossRef

20.

Wang J, Jiang Y, Zeng D, Zhou W, Hong X (2020) Prognostic value of plasma HMGB1 in ischemic stroke patients with cerebral ischemia-reperfusion injury after intravenous thrombolysis. J Stroke Cerebrovasc Dis 29(9):105055. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105055CrossRefPubMed

21.

Rashidian J et al (2009) Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J Neurosci 29(40):12497–12505. https://doi.org/10.1523/JNEUROSCI.3892-09.2009CrossRefPubMedPubMedCentral

22.

Shichita T et al (2012) Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18(6):911–917. https://doi.org/10.1038/nm.2749CrossRefPubMed

23.

Kuang X (2014) Ligustilide ameliorates neuroinflammation and brain injury in focal cerebral ischemia/reperfusion rats: involvement of inhibition of TLR4/peroxiredoxin 6 signaling. Free Radic Biol Med 71:165–175. https://doi.org/10.1016/j.freeradbiomed.2014.03.028CrossRefPubMed

24.

Nakamura K et al (2021) Extracellular DJ-1 induces sterile inflammation in the ischemic brain. PLoS Biol 19(5):e3000939. https://doi.org/10.1371/journal.pbio.3000939CrossRefPubMedPubMedCentral

25.

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A (2007) HumanTH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13(10):1173–1175. https://doi.org/10.1038/nm1651CrossRefPubMedPubMedCentral

26.

Richard S, Lapierre V, Girerd N, Bonnerot M, Burkhard PR, Lagerstedt L, Bracard S, Debouverie M, Turck N, Sanchez JC (2016) Diagnostic performance of peroxiredoxin 1 to determine time- of-onset of acute cerebral infarction. Sci Rep 6:38300. https://doi.org/10.1038/srep38300CrossRefPubMedPubMedCentral

27.

Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, Tardif MR, Cesaro A, Bose S (2014) DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation dur- ing influenza a virus infection: role of DDX21-TRIF-TLR4- MyD88 pathway. PLoS Pathog 10(1):e1003848. https://doi.org/10.1371/journal.ppat.1003848CrossRefPubMedPubMedCentral

28.

Loser K et al (2010) The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the develop- ment of autoreactive CD8+ T cells. Nat Med 16(6):713–717. https://doi.org/10.1038/nm.2150CrossRefPubMed

29.

Vogl T et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13(9):1042–1049. https://doi.org/10.1038/nm1638CrossRefPubMed

30.

Qiang X et al (2013) Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med 19(11):1489–1495. https://doi.org/10.1038/nm.3368CrossRefPubMedPubMedCentral

31.

Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrançois L, Li Z (2007) Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 26(2):215–226. https://doi.org/10.1016/j.immuni.2006.12.005CrossRefPubMedPubMedCentral

32.

Ekaney ML et al (2014) Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care 18(5):543. https://doi.org/10.1186/s13054-014-0543-8CrossRefPubMedPubMedCentral

33.

Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384. https://doi.org/10.1038/ni.1863CrossRefPubMed

34.

Zhang Q, RaoofM CY, Sumi Y, Sursal T, JungerW BK, Itagaki K, Hauser CJ (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464(7285):104–107. https://doi.org/10.1038/nature08780CrossRefPubMedPubMedCentral

35.

Oka T et al (2012) Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485(7397):251–255. https://doi.org/10.1038/nature10992CrossRefPubMedPubMedCentral

36.

Walko TD 3rd, Bola RA, Hong JD, Au AK, Bell MJ, Kochanek PM, Clark RS, Aneja RK (2014) Cerebrospinal fluid mitochon- drial DNA: a novel DAMP in pediatric traumatic brain injury. Shock 41(6):499–503. https://doi.org/10.1097/SHK.0000000000000160CrossRefPubMedPubMedCentral

37.

Hyakkoku K et al (2010) Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 171(1):258–267. https://doi.org/10.1016/j.neuroscience.2010.08.054CrossRefPubMed

38.

Brea D, Sobrino T, Rodríguez-Yáñez M, Ramos-Cabrer P, Agulla J, Rodríguez-González R, Campos F, Blanco M, Castillo J (2011) Toll- like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke. Clin Immunol 139(2):193–198. https://doi.org/10.1016/j.clim.2011.02.001CrossRefPubMed

39.

Gao D, Wu J, Wu Y-T, Du F, Aroh C, Yan N, Sun L, Chen ZJ (2013) Cyclic GMP- AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341(6148):903–906. https://doi.org/10.1126/science.1240933CrossRefPubMed

40.

Cai X, Chiu Y-H, Chen ZJ (2014) The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 54(2):289–296. https://doi.org/10.1016/j.molcel.2014.03.040CrossRefPubMed

41.

Chen Q, Sun L, Chen ZJ (2016) Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nat Immunol 17(10):1142–1149. https://doi.org/10.1038/ni.3558CrossRefPubMed

42.

Xia P, Wang S, Gao P, Gao G, Fan Z (2016) DNA sensor cGAS-mediated immune recognition. Protein Cell 7(11):777–791. https://doi.org/10.1007/s13238-016-0320-3CrossRefPubMedPubMedCentral

43.

AblasserA S-B, HemmerlingI HGL, Schmidt T, Latz E, Hornung V (2013) Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503(7477):530–534. https://doi.org/10.1038/nature12640CrossRef

44.

Li Q, Cao Y, Dang C, Han B, Han R, Ma H, Hao J, Wang L (2020) Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke. EMBO Mol Med 12(4):e11002. https://doi.org/10.15252/emmm.201911002CrossRefPubMedPubMedCentral

45.

Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, Kohsaka S (2007) Involvement of P2X4 and P2Y12 receptors in ATP- induced microglial chemotaxis. Glia 55(6):604–616. https://doi.org/10.1002/glia.20489CrossRefPubMed

46.

Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8(6):752–758. https://doi.org/10.1038/nn1472CrossRefPubMed

47.

Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing ofproIL- β. Mol Cell 10(2):417–426. https://doi.org/10.1016/S1097-2765(02)00599-3CrossRefPubMed

48.

Verma R, Cronin CG, Hudobenko J, Venna VR, McCullough LD, Liang BT (2017) Deletion ofthe P2X4 receptor is neuroprotective acutely, but induces a depressive phenotype during recovery from ischemic stroke. Brain Behav Immun 66:302–312. https://doi.org/10.1016/j.bbi.2017.07.155CrossRefPubMedPubMedCentral

49.

Webster CM, Hokari M, McManus A, Tang XN, Ma H, Kacimi R, Yenari MA (2013) Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS ONE 8(8):e70927. https://doi.org/10.1371/journal.pone.0070927CrossRefPubMedPubMedCentral

50.

Stewart CR et al (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–161. https://doi.org/10.1038/ni.1836CrossRefPubMed

51.

Uchida K (2013) Redox-derived damage-associated molecular patterns: ligand function of lipid peroxidation adducts. Redox Biol 1(1):94–96. https://doi.org/10.1016/j.redox.2012.12.005CrossRefPubMedPubMedCentral

52.

Gao S, Zhang R, Greenberg ME, Sun M, Chen X, Levison BS, Salomon RG, Hazen SL (2006) Phospholipid hydroxyalkenals, a subset of recently discovered endogenous CD36 ligands, spontaneously generate novel furan-containing phospholipids lacking CD36 binding activity in vivo. J Biol Chem 281(42):31298–31308. https://doi.org/10.1074/jbc.M604039200CrossRefPubMed

53.

Haider L, Fischer MT, Frishcer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134(Pt 7):1914–1924. https://doi.org/10.1093/brain/awr12CrossRefPubMedPubMedCentral

54.

Ho PP et al (2012) Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med 4(137):137ra73. https://doi.org/10.1126/scitranslmed.3003831CrossRefPubMedPubMedCentral

55.

Miller YI et al (2011) Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 108(2):235–248. https://doi.org/10.1161/CIRCRESAHA.110.223875CrossRefPubMedPubMedCentral

56.

Matt U et al (2013) WAVE1 mediates suppression of phagocytosis by phospholipid-derived DAMPs. J Clin Invest 123(7):3014–3024. https://doi.org/10.1172/JCI60681CrossRefPubMedPubMedCentral

57.

Cho S, Park EM, Febbraio M, Anrather J, Park L, Racchumi G, Silverstein R, Iadecola C (2005) The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 25(10):2504–2512. https://doi.org/10.1523/JNEUROSCI.0035-05.2005CrossRefPubMedPubMedCentral

58.

Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, Iadecola C (2010) Key role of CD36 in Toll-like receptor 2 signaling in cerebral ischemia. Stroke 41(5):898–904. https://doi.org/10.1161/STROKEAHA.109.572552CrossRefPubMedPubMedCentral

59.

West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467(7318):972–976. https://doi.org/10.1038/nature09421CrossRefPubMedPubMedCentral

60.

Clemens JA, Stephenson DT, Smalstig EB, Roberts EF, Johnstone EM, Sharp JD, Little SP, Kramer RL (1996) Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Stroke 27(3):527–535. https://doi.org/10.1161/01.STR.27.3.527CrossRefPubMed

61.

Bonventre JV, Huang Z, Taheri MR, O’Leary E, Li E, Moskowitz MA, Sapirstein A (1997) Reduced fertility and post ischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390(6660):622–625. https://doi.org/10.1038/37635CrossRefPubMed

62.

Muralikrishna Adibhatla R, Hatcher JF (2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free RadicvBiol Med 40(3):376–387. https://doi.org/10.1016/j.freeradbiomed.2005.08.044CrossRef

63.

Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP (2013) The resolution of inflammation. Nat Rev Immunol 13(1):59–66. https://doi.org/10.1038/nri3362CrossRefPubMed

64.

Zera KA, Buckwalter M (2020) The local and peripheral immune responses to stroke: implications for therapeutic development. Neurotherapeutics 17(2):414–435. https://doi.org/10.1007/s13311-020-00844-3CrossRefPubMedPubMedCentral

65.

Yu H, Cai Y, Zhong A, Zhang Y, Zhang J, Xu S (2021) The “dialogue” between central and peripheral immunity after ischemic stroke: focus on spleen. Front Immunol 12:792522. https://doi.org/10.3389/fimmu.2021.792522CrossRefPubMedPubMedCentral

66.

Liu F, Cheng X, Zhong S, Liu C, Jolkkonen J, Zhang X, Liang Y, Liu Z, Zhao C (2020) Communications between peripheral and the brain-resident immune system in neuronal regeneration after stroke. Front Immnol 11:1931. https://doi.org/10.3389/fimmu.2020.01931CrossRef

67.

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extra- cellular traps kill bacteria. Science 303(5663):1532–1535. https://doi.org/10.1126/science.1092385CrossRefPubMed

68.

Parker H, Albrett AM, Kettle AJ, Winterbourn CC (2012) Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence ofhydrogen peroxide. J Leukoc Biol 91(3):369–376. https://doi.org/10.1189/jlb.0711387CrossRefPubMed

69.

Wu X, Zeng H, Cai L, Chen G (2021) Role of the extracellular traps in central nervous system. Front Immunol 12:783882. https://doi.org/10.3389/fimmu.2021.783882CrossRefPubMedPubMedCentral

70.

Perez-de-Puig I, Miró-Mur F, Ferrer-Ferrer M, Gelpi E, Pedragosa J, Justicia C, Urra X, Chamorro A, Planas AM (2015) Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol 129(2):239–257. https://doi.org/10.1007/s00401-014-1381-0CrossRefPubMed

71.

Jorch SK, Kubes P (2017) An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med 23(3):279–287. https://doi.org/10.1038/nm.4294CrossRefPubMed

72.

Wang R et al (2021) Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke. Blood 138(1):91–103. https://doi.org/10.1182/blood.2020008913CrossRefPubMedPubMedCentral

73.

Laridan E, Denorme F, Desender L, Francois O, Andersson T, Deckmyn H, Vanhoorelbeke K, De Meyer SF (2017) Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 82(2):223–232. https://doi.org/10.1002/ana.24993CrossRefPubMed

74.

Pertiwi KR, de Boer OJ, Mackaaij C, Pabittei DR, de Winter RJ, Li X, van der Wal AC (2019) Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. J Pathol 247(4):505–512. https://doi.org/10.1002/path.5212CrossRefPubMedPubMedCentral

75.

Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22(9):391–397. https://doi.org/10.1016/S0166-2236(99)01401-0CrossRefPubMed

76.

Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796–808. https://doi.org/10.1038/nm.2399CrossRefPubMedPubMedCentral

77.

Lambertsen KL, Biber K, Finsen B (2012) Inflammatory cyto- kines in experimental and human stroke. J Cereb Blood Flow Metab 32(9):1677–2169. https://doi.org/10.1038/jcbfm.2012.88CrossRefPubMedPubMedCentral

78.

Wattananit S et al (2016) Monocyte-derived macrophages contribute to spontaneous long-term functional recovery after stroke in mice. J Neurosci 36(15):4182–4195. https://doi.org/10.1523/JNEUROSCI.4317-15.2016CrossRefPubMedPubMedCentral

79.

Shichita T et al (2009) Pivotal role of cerebral interleukin-17- producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15(8):946–950. https://doi.org/10.1038/nm.1999CrossRefPubMed

80.

Smirkin A et al (2010) Iba1+/NG2+ macrophage-like cells expressing a variety of neuroprotective factors ameliorate ischemic damage of the brain. J Cereb Blood Flow Metab 30(3):603–615. https://doi.org/10.1038/jcbfm.2009.233CrossRefPubMed

81.

Shichita T et al (2017) MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat Med 23(6):723–732. https://doi.org/10.1038/nm.4312CrossRefPubMed

82.

Iliff JJ et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl Med 4(147):147ra111. https://doi.org/10.1126/scitranslmed.3003748CrossRefPubMedPubMedCentral

83.

Albargothy NJ, Johnston DA, MacGregor-Sharp M, Weller RO, Verma A, Hawkes CA, Carare RO (2018) Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol 136(1):136–152. https://doi.org/10.1007/s00401-018-1862-7CrossRef

84.

Lv T, Zhao B, Hu Q, Zhang X (2021) The glymphatic system: a novel therapeutic target for stroke treatment. Front Aging Neurosci 13:689098. https://doi.org/10.3389/fnagi.2021.689098CrossRefPubMedPubMedCentral

85.

Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J (2015) The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85(4):703–709. https://doi.org/10.1016/j.neuron.2015.01.013CrossRefPubMed

86.

Pomeshchik Y, KidinI KP, Savchenko E, Jaronen M, Lehtonen S, Wojciechowski S, Kanninen K, Koistinaho J, Malm T (2015) Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun 44:68–81. https://doi.org/10.1016/j.bbi.2014.08.002CrossRefPubMed

87.

Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, Wu X (2015) Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res 1597:86–94. https://doi.org/10.1016/j.brainres.2014.12.005CrossRefPubMed

88.

Fu AKY et al (2016) IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A 113(19):E2705-2713. https://doi.org/10.1073/pnas.1604032113CrossRefPubMedPubMedCentral

89.

Luheshi NM, Kovács KJ, Lopez-Castejon G, Brough D, Denes A (2011) Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localized to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation 29(8):186. https://doi.org/10.1186/1742-2094-8-186CrossRef

90.

Yang Y et al (2017) ST2/IL-33-dependent microglial response limits acute ischemic brain injury. J Neurosci 37(18):4692–4704. https://doi.org/10.1523/JNEUROSCI.3233-16.2017CrossRefPubMedPubMedCentral

91.

Ito M et al (2019) Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature 565(7738):246–250. https://doi.org/10.1038/s41586-018-0824-5CrossRefPubMed

92.

Chen H et al (2016) IL-10 Promotes neurite outgrowth and synapse formation in cultured cortical neurons after the oxygen-glucose deprivation via JAK1/STAT3 pathway. Sci Rep 6:30459. https://doi.org/10.1038/srep30459CrossRefPubMedPubMedCentral

93.

Vainchtein ID et al (2018) Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 359(6381):1269–1273. https://doi.org/10.1126/science.aal3589CrossRefPubMedPubMedCentral

94.

Hayakawa K, Qiu J, Lo EH (2010) Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 1207:50–57. https://doi.org/10.1111/j.1749-6632.2010.05728.xCrossRefPubMedPubMedCentral

95.

Passalacqua M, Atrone M, Picotti GB, Del Rio M, Sparatore B, Melloni E, Pontremoli S (1998) Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation. Neuroscience 82(4):1021–1028. https://doi.org/10.1016/s0306-4522(97)00352-7CrossRefPubMed

96.

Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J (2005) Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166(4):1259–1263. https://doi.org/10.1016/S0002-9440(10)62344-9CrossRefPubMedPubMedCentral

97.

Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H (2000) Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275(51):40096–40105. https://doi.org/10.1074/jbc.M006993200CrossRefPubMed

98.

Okun E, Griffioen KJ, Mattson MP (2011) Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 34(5):269–281. https://doi.org/10.1016/j.tins.2011.02.005CrossRefPubMedPubMedCentral

99.

McKimmie CS, Fazakerley JK (2005) In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J Neuroimmunol 169(1–2):116–125. https://doi.org/10.1016/j.jneuroim.2005.08.006CrossRefPubMed

100.

Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP (2005) TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 175(7):4320–4330. https://doi.org/10.4049/jimmunol.175.7.4320CrossRefPubMed

101.

Gorina R, Font-Nieves M, Márquez-Kisinousky L, Santalucia T, Planas AM (2011) Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling MAPK, and Jak1/Stat1 pathways. Glia 59(2):242–255. https://doi.org/10.1002/glia.21094CrossRefPubMed

102.

Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T (2010) Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci U S A 107(25):11555–11560. https://doi.org/10.1073/pnas.1006496107CrossRefPubMedPubMedCentral

103.

Tang SC et al (2007) Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 104(34):13798–13803. https://doi.org/10.1073/pnas.0702553104CrossRefPubMedPubMedCentral

104.

Cameron JS et al (2007) Toll-like receptor 3 is a potent negative regulator ofaxonal growth in mammals. J Neurosci 27(47):13033–13041. https://doi.org/10.1523/JNEUROSCI.4290-06.2007CrossRefPubMedPubMedCentral

105.

MaY LJ, Chiu I, Wang Y, Sloane JA, Lü J, Kosaras B, Sidman RL, Volpe JJ, Vartanian T (2006) Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J Cell Biol 175(2):209–215. https://doi.org/10.1083/jcb.200606016CrossRef

106.

Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132(4):645–660. https://doi.org/10.1016/j.cell.2008.01.033CrossRefPubMed

107.

Kojima T, Hirota Y, Ema M, Takahashi S, Miyoshi I, Okano H, Sawamoto K (2010) Subventricular zone-derived neural progenitor cells migrate along a blood vessel scaffold toward the post-stroke striatum. Stem Cell 28(3):545–554. https://doi.org/10.1002/stem.306CrossRef

108.

Lathia JD et al (2008) Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. J Neurosci 28(51):13978–13984. https://doi.org/10.1523/JNEUROSCI.2140-08.2008CrossRefPubMedPubMedCentral

109.

Okun E et al (2010) TLR2 activation inhibits embryonic neural progenitor cell proliferation. J Neurochem 114(2):462–474. https://doi.org/10.1111/j.1471-4159.2010.06778.xCrossRefPubMedPubMedCentral

110.

Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, Schwartzet M (2007) Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 9(9):1081–1088. https://doi.org/10.1038/ncb1629CrossRefPubMed

Title: Role of alarmins in poststroke inflammation and neuronal repair
Authors: Seiichiro Sakai
Takashi Shichita
Publication date: 26-09-2022
Publisher: Springer Berlin Heidelberg
Keywords: Stroke
Cytokines
Published in: Seminars in Immunopathology / Issue 3/2023
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-022-00961-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Unveiling the immunopathology of stroke: a comprehensive view on brain-immune interaction

Sex differences in the inflammatory response to stroke

The role of the ATP-adenosine axis in ischemic stroke

Role of glia and extracellular matrix in controlling neuroplasticity in the central nervous system

The immunopathology of B lymphocytes during stroke-induced injury and repair

Thromboinflammatory challenges in stroke pathophysiology

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage